Meta-analysis of randomized trials of angioedema as an adverse event of renin-angiotensin system inhibitors

Harikrishna Makani, Franz H. Messerli, Jorge E. Romero, Omar Wever-Pinzon, Aleksander Korniyenko, Ronaldo Sevilla Berrios, Sripal Bangalore

Research output: Contribution to journalArticle

91 Citations (Scopus)

Abstract

Angioedema is a rare, potentially life-threatening adverse event of renin-angiotensin system inhibitors. The objective of the present study was to determine the risk of angioedema from randomized clinical trials. A PubMed/CENTRAL/EMBASE search was made for randomized clinical trials from 1980 to October 2011 in patients on angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), or direct renin inhibitor (DRI). Trials with a total number of patients <100 and a duration of <8 weeks were included for analysis. Incidence of angioedema was pooled by weighing the incident rate of each trial by the inverse of the variance. Twenty-six trials with 74,857 patients in the ACE inhibitor arm with 232,523 person-years of follow-up, 19 trials with 35,479 patients on ARB with 122,293 person-years of follow-up, and 2 trials with 5,141 patients on DRI with 1,735 person-years of follow-up met the inclusion criteria and were included in the analysis. In head-to-head comparison in 7 trials, risk of angioedema with ACE inhibitors was 2.2 times higher than with ARBs (95% confidence interval [CI] 1.5 to 3.3). With ACE inhibitors and ARBs, incidence of angioedema was higher in heart failure trials compared to hypertension or coronary artery disease trials without heart failure (p <0.0001). Weighted incidence of angioedema with ACE inhibitors was 0.30% (95% CI 0.28 to 0.32) compared to 0.11% (95% CI 0.09 to 0.13) with ARBs, 0.13% (95% CI 0.08 to 0.19) with DRIs, and 0.07% with placebo (95% CI 0.05 to 0.09). In conclusion, incidence of angioedema with ARBs and DRI was <1/2 than that with ACE inhibitors and not significantly different from placebo. Incidence of angioedema was higher in patients with heart failure compared to those without heart failure with ACE inhibitors and ARBs.

Original languageEnglish (US)
Pages (from-to)383-391
Number of pages9
JournalAmerican Journal of Cardiology
Volume110
Issue number3
DOIs
StatePublished - Aug 1 2012
Externally publishedYes

Fingerprint

Angioedema
Renin-Angiotensin System
Angiotensin Receptor Antagonists
Meta-Analysis
Angiotensin-Converting Enzyme Inhibitors
Confidence Intervals
Heart Failure
Renin
Incidence
Randomized Controlled Trials
Placebos
PubMed
Coronary Artery Disease
Hypertension

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Meta-analysis of randomized trials of angioedema as an adverse event of renin-angiotensin system inhibitors. / Makani, Harikrishna; Messerli, Franz H.; Romero, Jorge E.; Wever-Pinzon, Omar; Korniyenko, Aleksander; Berrios, Ronaldo Sevilla; Bangalore, Sripal.

In: American Journal of Cardiology, Vol. 110, No. 3, 01.08.2012, p. 383-391.

Research output: Contribution to journalArticle

Makani, Harikrishna ; Messerli, Franz H. ; Romero, Jorge E. ; Wever-Pinzon, Omar ; Korniyenko, Aleksander ; Berrios, Ronaldo Sevilla ; Bangalore, Sripal. / Meta-analysis of randomized trials of angioedema as an adverse event of renin-angiotensin system inhibitors. In: American Journal of Cardiology. 2012 ; Vol. 110, No. 3. pp. 383-391.
@article{e5323bb690e64bcca85851ed98e02bef,
title = "Meta-analysis of randomized trials of angioedema as an adverse event of renin-angiotensin system inhibitors",
abstract = "Angioedema is a rare, potentially life-threatening adverse event of renin-angiotensin system inhibitors. The objective of the present study was to determine the risk of angioedema from randomized clinical trials. A PubMed/CENTRAL/EMBASE search was made for randomized clinical trials from 1980 to October 2011 in patients on angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), or direct renin inhibitor (DRI). Trials with a total number of patients <100 and a duration of <8 weeks were included for analysis. Incidence of angioedema was pooled by weighing the incident rate of each trial by the inverse of the variance. Twenty-six trials with 74,857 patients in the ACE inhibitor arm with 232,523 person-years of follow-up, 19 trials with 35,479 patients on ARB with 122,293 person-years of follow-up, and 2 trials with 5,141 patients on DRI with 1,735 person-years of follow-up met the inclusion criteria and were included in the analysis. In head-to-head comparison in 7 trials, risk of angioedema with ACE inhibitors was 2.2 times higher than with ARBs (95{\%} confidence interval [CI] 1.5 to 3.3). With ACE inhibitors and ARBs, incidence of angioedema was higher in heart failure trials compared to hypertension or coronary artery disease trials without heart failure (p <0.0001). Weighted incidence of angioedema with ACE inhibitors was 0.30{\%} (95{\%} CI 0.28 to 0.32) compared to 0.11{\%} (95{\%} CI 0.09 to 0.13) with ARBs, 0.13{\%} (95{\%} CI 0.08 to 0.19) with DRIs, and 0.07{\%} with placebo (95{\%} CI 0.05 to 0.09). In conclusion, incidence of angioedema with ARBs and DRI was <1/2 than that with ACE inhibitors and not significantly different from placebo. Incidence of angioedema was higher in patients with heart failure compared to those without heart failure with ACE inhibitors and ARBs.",
author = "Harikrishna Makani and Messerli, {Franz H.} and Romero, {Jorge E.} and Omar Wever-Pinzon and Aleksander Korniyenko and Berrios, {Ronaldo Sevilla} and Sripal Bangalore",
year = "2012",
month = "8",
day = "1",
doi = "10.1016/j.amjcard.2012.03.034",
language = "English (US)",
volume = "110",
pages = "383--391",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Meta-analysis of randomized trials of angioedema as an adverse event of renin-angiotensin system inhibitors

AU - Makani, Harikrishna

AU - Messerli, Franz H.

AU - Romero, Jorge E.

AU - Wever-Pinzon, Omar

AU - Korniyenko, Aleksander

AU - Berrios, Ronaldo Sevilla

AU - Bangalore, Sripal

PY - 2012/8/1

Y1 - 2012/8/1

N2 - Angioedema is a rare, potentially life-threatening adverse event of renin-angiotensin system inhibitors. The objective of the present study was to determine the risk of angioedema from randomized clinical trials. A PubMed/CENTRAL/EMBASE search was made for randomized clinical trials from 1980 to October 2011 in patients on angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), or direct renin inhibitor (DRI). Trials with a total number of patients <100 and a duration of <8 weeks were included for analysis. Incidence of angioedema was pooled by weighing the incident rate of each trial by the inverse of the variance. Twenty-six trials with 74,857 patients in the ACE inhibitor arm with 232,523 person-years of follow-up, 19 trials with 35,479 patients on ARB with 122,293 person-years of follow-up, and 2 trials with 5,141 patients on DRI with 1,735 person-years of follow-up met the inclusion criteria and were included in the analysis. In head-to-head comparison in 7 trials, risk of angioedema with ACE inhibitors was 2.2 times higher than with ARBs (95% confidence interval [CI] 1.5 to 3.3). With ACE inhibitors and ARBs, incidence of angioedema was higher in heart failure trials compared to hypertension or coronary artery disease trials without heart failure (p <0.0001). Weighted incidence of angioedema with ACE inhibitors was 0.30% (95% CI 0.28 to 0.32) compared to 0.11% (95% CI 0.09 to 0.13) with ARBs, 0.13% (95% CI 0.08 to 0.19) with DRIs, and 0.07% with placebo (95% CI 0.05 to 0.09). In conclusion, incidence of angioedema with ARBs and DRI was <1/2 than that with ACE inhibitors and not significantly different from placebo. Incidence of angioedema was higher in patients with heart failure compared to those without heart failure with ACE inhibitors and ARBs.

AB - Angioedema is a rare, potentially life-threatening adverse event of renin-angiotensin system inhibitors. The objective of the present study was to determine the risk of angioedema from randomized clinical trials. A PubMed/CENTRAL/EMBASE search was made for randomized clinical trials from 1980 to October 2011 in patients on angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), or direct renin inhibitor (DRI). Trials with a total number of patients <100 and a duration of <8 weeks were included for analysis. Incidence of angioedema was pooled by weighing the incident rate of each trial by the inverse of the variance. Twenty-six trials with 74,857 patients in the ACE inhibitor arm with 232,523 person-years of follow-up, 19 trials with 35,479 patients on ARB with 122,293 person-years of follow-up, and 2 trials with 5,141 patients on DRI with 1,735 person-years of follow-up met the inclusion criteria and were included in the analysis. In head-to-head comparison in 7 trials, risk of angioedema with ACE inhibitors was 2.2 times higher than with ARBs (95% confidence interval [CI] 1.5 to 3.3). With ACE inhibitors and ARBs, incidence of angioedema was higher in heart failure trials compared to hypertension or coronary artery disease trials without heart failure (p <0.0001). Weighted incidence of angioedema with ACE inhibitors was 0.30% (95% CI 0.28 to 0.32) compared to 0.11% (95% CI 0.09 to 0.13) with ARBs, 0.13% (95% CI 0.08 to 0.19) with DRIs, and 0.07% with placebo (95% CI 0.05 to 0.09). In conclusion, incidence of angioedema with ARBs and DRI was <1/2 than that with ACE inhibitors and not significantly different from placebo. Incidence of angioedema was higher in patients with heart failure compared to those without heart failure with ACE inhibitors and ARBs.

UR - http://www.scopus.com/inward/record.url?scp=84863986170&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863986170&partnerID=8YFLogxK

U2 - 10.1016/j.amjcard.2012.03.034

DO - 10.1016/j.amjcard.2012.03.034

M3 - Article

C2 - 22521308

AN - SCOPUS:84863986170

VL - 110

SP - 383

EP - 391

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 3

ER -